European Commercial Roll-out continues with Poland Agreement
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Memphasys Ltd has announced an exclusive commercialisation agreement with TK Biotech Sp. z o.o. for the Felix™ System in Poland, marking a significant step in its European expansion efforts. The agreement includes a minimum contracted value over a two-year term and follows the company's previous agreements in Italy and the United Kingdom. The partnership aims to enhance the accessibility of reproductive technologies in Poland's expanding IVF market, supported by a government-funded IVF program. Memphasys plans to drive recurring revenue through contracted quarterly purchases after an initial evaluation period.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Memphasys
- Exclusive Thailand Commercialisation Agreement Secured
- UK Market Entry & Acceleration of Commercial Expansion
- Successful $1.2M Placement and Convertible Note Extended
- Memphasys Executes Supply Agreement with Monash IVF Group
- South-East Asian Commercialization Agreement Secured
Later from Memphasys
- Pivotal Felix Study Receives First Scientific Presentation
- Felix Registration Achieved in Vietnam and Cartridge Order
- Results of General Meeting
- Felix Early Thai FDA Approval, Commercial Launch Accelerates
- Appendix 4E and 2026 Annual Report
Follow Memphasys into a list and get an email when it puts out news.
Follow Memphasys